Cancer Vaccines

• 

  Subject Areas on Research

  • A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response. 
  • A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo. 
  • A global approach to tumor immunology. 
  • A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors. 
  • A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2. 
  • A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. 
  • A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. 
  • A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. 
  • A promising cancer vaccine. 
  • A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. 
  • A study of dendritic and endothelial cell interactions in colon cancer in a cell line and small mammal model. 
  • A urologic oncology roundtable discussion: issues to consider in choosing treatment for metastatic castration-resistant prostate cancer. 
  • A year of successful cancer vaccines points to a path forward. 
  • Advances and challenges: dendritic cell vaccination strategies for glioblastoma. 
  • Advances in immunotherapy for pancreatic cancer: 2013. 
  • Alphavirus Replicon Particle Vaccine Breaks B Cell Tolerance and Rapidly Induces IgG to Murine Hematolymphoid Tumor Associated Antigens. 
  • An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity. 
  • An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. 
  • Anti-epidermal growth factor receptor therapy for glioblastoma in adults. 
  • Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA. 
  • Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. 
  • Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. 
  • Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. 
  • Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. 
  • BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. 
  • Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity. 
  • Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. 
  • Bispecific antibodies engage T cells for antitumor immunotherapy. 
  • Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. 
  • CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy. 
  • CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. 
  • CEA loaded dendritic cell vaccines. 
  • Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions. 
  • Cancer vaccines. 
  • Cell-based vaccines for the stimulation of immunity to metastatic cancers. 
  • Cellular and biological therapies of gastrointestinal tumors: overview of clinical trials. 
  • Characterization of CD8(-) HLA class I/epitope tetrameric complexes binding T cells. 
  • Checkpoint blockade in combination with cancer vaccines. 
  • Clinical applications of a peptide-based vaccine for glioblastoma. 
  • Clinical applications of dendritic cell vaccines. 
  • Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects. 
  • Combination strategies to maximize the benefits of cancer immunotherapy. 
  • Combining cancer vaccines with chemotherapy. 
  • Coming together at the hinges: Therapeutic prospects of IgG3. 
  • Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. 
  • Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. 
  • Current immunotherapeutic strategies in colon cancer. 
  • Current immunotherapeutic strategies in malignant melanoma. 
  • Cytokine and immuno-gene therapy for solid tumors. 
  • DNA and RNA modified dendritic cell vaccines. 
  • Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. 
  • Delivery of Synthetic mRNA Encoding FOXP3 Antigen into Dendritic Cells for Inflammatory Breast Cancer Immunotherapy. 
  • Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging. 
  • Dendritic cell gene therapy. 
  • Dendritic cell vaccines targeting survivin in head and neck cancer. 
  • Dendritic cell vaccines. 
  • Dendritic cell-based immunization for cancer therapy. 
  • Dendritic cell-based immunotherapy. 
  • Dendritic cell-tumor cell fusion vaccines. 
  • Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. 
  • Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. 
  • Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. 
  • Designing effective vaccines for colorectal cancer. 
  • Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. 
  • Direct detection of cellular immune responses to cancer vaccines. 
  • Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients. 
  • Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity. 
  • EGFRvIII-targeted vaccination therapy of malignant glioma. 
  • Editorial on "heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial". 
  • Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells. 
  • Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. 
  • Emerging immunotherapies for glioblastoma. 
  • Emerging therapeutic targets for patients with advanced prostate cancer. 
  • Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity. 
  • Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. 
  • Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. 
  • Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. 
  • Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma. 
  • Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. 
  • Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon. 
  • Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. 
  • Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. 
  • Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients. 
  • First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. 
  • Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. 
  • Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. 
  • From the RNA world to the clinic. 
  • Fulfilling the promise of immunotherapy. 
  • Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. 
  • Functional heterogeneity of vaccine-induced CD8(+) T cells. 
  • Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines. 
  • Gene therapy for lung cancer. 
  • Generation of Tumor Targeted Dendritic Cell Vaccines with Improved Immunogenic and Migratory Phenotype. 
  • Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. 
  • Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. 
  • Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. 
  • HER2 dendritic cell vaccines. 
  • HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression. 
  • Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade. 
  • Highlights in advanced prostate cancer from the 2014 AUA and ASCO meetings. 
  • Hormone refractory prostate cancer: Management and advances. 
  • How does sipuleucel-T alter our clinical practice? 
  • Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice. 
  • Immune evasion pathways and the design of dendritic cell-based cancer vaccines. 
  • Immune monitoring. 
  • Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. 
  • Immuno-synergy? Neoantigen vaccines and checkpoint blockade in glioblastoma. 
  • Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy. 
  • Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. 
  • Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. 
  • Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. 
  • Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. 
  • Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. 
  • Immunomodulation for glioblastoma. 
  • Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. 
  • Immunotherapy for gynaecological malignancies. 
  • Immunotherapy for osteosarcoma: Where do we go from here? 
  • Immunotherapy of cancer with dendritic cell-based vaccines. 
  • Immunotherapy of cancer with dendritic-cell-based vaccines. 
  • Immunotherapy of malignant brain tumors. 
  • Immunotherapy of surgical malignancies. 
  • Immunotherapy with tumor vaccines for the treatment of malignant gliomas. 
  • Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. 
  • Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model. 
  • Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growth. 
  • In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. 
  • Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. 
  • Increasing vaccine potency through exosome antigen targeting. 
  • Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. 
  • Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine. 
  • Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. 
  • Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. 
  • Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. 
  • Induction of type I IFN is required for overcoming tumor-specific T-cell tolerance after stem cell transplantation. 
  • Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors. 
  • Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. 
  • Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. 
  • Is There a Role for Immunotherapy in Central Nervous System Cancers? 
  • Isolation and generation of human dendritic cells. 
  • Kinetics of TCR use in response to repeated epitope-specific immunization. 
  • Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination. 
  • Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. 
  • Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases. 
  • Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. 
  • MCA106 fibrosarcoma cells transduced with granulocyte/macrophage colony-stimulating factor are not superior to the wild-type cells in suppressing the growth of hepatic metastases. 
  • MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. 
  • Macrophage colony-stimulating factor can modulate immune responses and attract dendritic cells in vivo. 
  • Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. 
  • Messenger RNA (mRNA) nanoparticle tumour vaccination. 
  • Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine. 
  • Modeling flow cytometry data for cancer vaccine immune monitoring. 
  • Modulation of specific active immunization against murine melanoma using recombinant cytokines. 
  • Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. 
  • Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines. 
  • Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. 
  • Monocytes as a Cellular Vaccine Platform to Induce Antitumor Immunity. 
  • Multiepitope supramolecular peptide nanofibers eliciting coordinated humoral and cellular antitumor immune responses. 
  • Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. 
  • NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. 
  • New drugs in prostate cancer. 
  • New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. 
  • Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. 
  • Novel immunotherapeutic strategies in development for renal cell carcinoma. 
  • Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy. 
  • Novel therapeutic approaches to advanced prostate cancer. 
  • Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. 
  • Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular antigen processing. 
  • Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. 
  • Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution. 
  • Our failure to advance new treatments for glioma to market. 
  • Overview of melanoma vaccines and promising approaches. 
  • PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model. 
  • Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. 
  • Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential? 
  • Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. 
  • Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. 
  • Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. 
  • Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. 
  • Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. 
  • Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report. 
  • Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells. 
  • Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. 
  • Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. 
  • Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors. 
  • Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer. 
  • Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy. 
  • Preparation of peptide-loaded dendritic cells for cancer immunotherapy. 
  • Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines. 
  • Programming human dendritic cells with mRNA. 
  • Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients. 
  • Promising vaccines for treating glioblastoma. 
  • Prospect of rindopepimut in the treatment of glioblastoma. 
  • Prostate cancer gene therapy. 
  • Proteomics for monitoring immune responses to cancer vaccines. 
  • Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. 
  • Putting Provenge in perspective. 
  • Putting Provenge in perspective. 
  • Quantitating therapeutically relevant T-cell responses to cancer vaccines. 
  • Questionable relevance of gamma delta T lymphocytes in renal cell carcinoma. 
  • RNA transfected dendritic cells as cancer vaccines. 
  • RNA-Based Vaccines in Cancer Immunotherapy. 
  • RNA-transfected dendritic cells in cancer immunotherapy. 
  • RNA-transfected dendritic cells. 
  • Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer. 
  • Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. 
  • Recent areas of development for dendritic cell vaccines. 
  • Recent clinical progress in virus-based therapies for cancer. 
  • Recent developments in therapeutic cancer vaccines. 
  • Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. 
  • Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma. 
  • Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. 
  • Review. Colon cancer vaccines: an update. 
  • Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. 
  • Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. 
  • Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme. 
  • Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. 
  • Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. 
  • Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. 
  • Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide. 
  • Short-term kinetics of tumor antigen expression in response to vaccination. 
  • Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy. 
  • Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. 
  • Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens. 
  • Status of activation of circulating vaccine-elicited CD8+ T cells. 
  • Status of colon cancer vaccines. [An interview with Michael Morse by H&O]. 
  • Stem cell transplantation for multiple myeloma. 
  • Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. 
  • Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. 
  • Superantigen enhanced protection against a weak tumor-specific melanoma antigen: implications for prophylactic vaccination against cancer. 
  • Surrogate markers of effective anti-tumor immunity. 
  • Surrogate markers of response to cancer immunotherapy. 
  • Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy. 
  • Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. 
  • Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. 
  • Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. 
  • T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma. 
  • T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance. 
  • T-cell-directed cancer vaccines: the melanoma model. 
  • Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus. 
  • Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies. 
  • Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. 
  • Technology evaluation: BLP-25, Biomira Inc. 
  • Technology evaluation: Theratope, Biomira Inc. 
  • Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. 
  • Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. 
  • The Landscape of Cell and Gene Therapies for Solid Tumors. 
  • The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. 
  • The Preuss Foundation Seminar on vaccine therapy for malignant primary brain tumors. February 15-17, 1998, La Jolla, Calif. 
  • The Safety of available immunotherapy for the treatment of glioblastoma. 
  • The current state of immunotherapy for gliomas: an eye toward the future. 
  • The development of therapeutic and preventive vaccines for gastric cancer and Helicobacter pylori. 
  • The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. 
  • Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells. 
  • Tissue engineered cancer metastases as cancer vaccine to improve cancer immunotherapy. 
  • Toward effective immunotherapy for the treatment of malignant brain tumors. 
  • Translational Research Working Group developmental pathway for immune response modifiers. 
  • Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. 
  • Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine. 
  • Tumor microenvironment and the immune response. 
  • Tumor microenvironment: what have we learned studying the immune response in this puzzling battlefield? 
  • Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. 
  • Tumors as elusive targets of T-cell-based active immunotherapy. 
  • Understanding the response to immunotherapy in humans. 
  • Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. 
  • Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. 
  • Vaccination strategies for neuro-oncology. 
  • Vaccination to Prevent Cancer. 
  • Vaccination with T cell-defined antigens. 
  • Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. 
  • Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. 
  • Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. 
  • Vaccine Therapies for Cancer: Then and Now. 
  • Vaccine Therapy, Oncolytic Viruses, and Gliomas. 
  • Vaccine therapy in non-small-cell lung cancer. 
  • Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. 
  • Vaccine-based immunotherapeutic approaches to gliomas and beyond. 
  • Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens. 
  • Virus-based therapies for colon cancer. 
  • WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy. 
  • White paper on microbial anti-cancer therapy and prevention. 
  • Whole blood cells loaded with messenger RNA as an anti-tumor vaccine. 
• 

  Keywords of People

  • Halabi, Susan, Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Hoimes, Christopher, Instructor in the Department of Medicine, Medicine, Medical Oncology
  • Inman, Brant Allen, Professor of Surgery, Surgery, Urology
  • Khasraw, Mustafa, Professor of Neurosurgery, Medicine, Medical Oncology
  • Lee, Walter T, Professor of Head and Neck Surgery & Communication Sciences, Radiation Oncology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Mosca, Paul Joseph, Associate Professor of Surgery, Surgical Oncology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering